Ipilimumab
Male Reproductive System Neoplasm
Australian and New Zealand Urogenital and Prostate Cancer Trials Groupmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Male Reproductive System Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Psma-Hbed-Cc Alf-18 Alessandro D'Agnolo | Phase 2 | B |
STI571 Novartis Pharmaceuticals | Phase 2 | B |
Ixabepilone Cedars-Sinai Medical Center | Phase 2 | CCC |
Pembrolizumab Nasser Hanna, M.D. | Phase 2 | CCC |
Nivolumab Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →